Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Table 3 Drug exposure in patients with OS ≥24 versus < 24 months in the axitinib titration arm

Parameter	OS ≥24 months n = 33	OS < 24 months n = 20^a
Days on treatment,^b median (range)	925 (106–1795)	85 (42–456)
Days on drug,^c median (range)	925 (91–1688)	84 (38–456)
Average daily dose, median (range), mg	13.9 (4.9–23.4)	13.0 (9.9–19.2)
Relative dose intensity, median (range), %	135 (46–224)	125 (83–192)
Patients with dose decrease < 5 mg bid, n (%)	10 (30)	1 (5)

Abbreviations: bid twice daily, OS overall survival
^aExcluded 3 patients who were censored < 24 months in OS
^bTime period starting from date of the first dose to date of the last dose or data cutoff
^cTotal number of days in which axitinib was actually administered

ISSN: 1471-2407